Best Biotechnology Integrated Ad Campaign

Oncolyze is developing a disruptive technology for the treatment of cancer. Oncolyze is on a mission to provide cancer patients with a novel therapy that selectively attacks cancer cells and pokes holes in their cell membrane, causing these cancer cells to explode and die, while leaving normal cells intact. Oncolyze has launched a Regulation A+ funding campaign to spread awareness of OM-301 among cancer patients, healthcare professionals, and the investment community. The Invest in Oncolyze campaign consists of the following assets:
- A stand-alone campaign website, separate from the corporate website
- A one-page executive summary of the investment opportunity
- A pitch deck
- A campaign video
- A social media presence

------------
Note: You should read the Offering Circular (https://lnkd.in/ezWEQbuX ) and Risks (https://lnkd.in/e_N2nCtc) related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Contributors:

Head of Marketing, TNG Creative:	Mika Stojanovic
Head of Strategy, TNG Creative:	Alex Stojanovic
Creative Director, TNG Creative:	Kosta Rakicevic
Senior Graphic Designer, TNG Creative:	Nina Hadzivukovic
Lead Developer, TNG Creative:	Mladen Prijic
Project Manager, TNG Creative:	Marko Kostic

TNG CREATIVE

Website: https://www.tngcreative.com/

Location: United States

About the Agency:

TNG Creative is a healthcare-focused, boutique consultancy that bridges the gap between STRATEGY + CREATIVE + SCIENCE. We recognize the evolving needs and challenges of life science companies at all stages, and we proactively help our clients navigate them by leveraging the full multichannel spectrum. Our lean and nimble multidisciplinary team curates scientific data and transforms it into eye-catching stories that effectively communicate scientific and commercial value, not only to HCPs and patients but also to shareholders, investors, and other key audiences.